AstraZeneca AZN and Abbott Laboratories have ended their co-development license after discontinuing development of their treatment for mixed dyslipidemia.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
